Secular trends of endoscopic sleeve gastroplasty: analysis of the MBSAQIP database

1

The obesity epidemic affects nearly 4 in 10 adults in the U.S., with bariatric surgery being underutilized by eligible patients.
2

Endoscopic sleeve gastroplasty (ESG) is a safe and effective treatment for obesity, particularly for patients who are poor surgical candidates.
3

The number of ESG procedures increased by 50.5% from 2020 to 2023, indicating growing adoption of this treatment.
4

The mean BMI of patients undergoing ESG rose from 37.8 to 40.8 kg/m2 between 2020 and 2023, reflecting worsening obesity trends.
5

Despite increased BMI and comorbidities, the incidence of 30-day post-procedural adverse events remained statistically unchanged during the study.

1